Skip to content

Risk factors for gynaecomastia include hepatitis C, fat loss, and low testosterone

Detectable viral load risk factor for new illness in those who start HAART with CD4 below 50

ICAAC: Tipranavir / ritonavir superior to other boosted PIs in salvage therapy

ICAAC: Kaletra: stability and potency decline rapidly in hot climates

ICAAC: Tolerability key to superior showing of tenofovir/FTC in head to head match with Combivir

ICAAC: Glaxo unveils chemokine blocker as interest in new drug class hots up

US HIV treatment guidelines revised

ICAAC: When to use T-20: new analysis shows risk of leaving it too late

ICAAC: Tenofovir and Trizivir effective and well-tolerated in patients who fail first regimen